Extracellular vesicle surface display of αPD-L1 and αCD3 antibodies via engineered late domain-based scaffold to activate T-cell anti-tumor immunity
Quick Facts
- Publication title: Extracellular vesicle surface display of αPD-L1 and αCD3 antibodies via engineered late domain-based scaffold to activate T-cell anti-tumor immunity
- Journal: J Extracell Vesicles
- Year: 2024
- DOI: 10.1002/jev2.12490
- PMID/PMCID: 39051742; PMC11270581
Research overview
Inspired by the similarity of biogenesis between EVs and viruses, we developed a synthetic, Late domain-based EV scaffold protein that enables the display of a set of single chain variable fragments (scFvs) on the EV surface. Our study suggested that the LEAP scaffold may serve as a platform for EV surface display and could be applied for a broad range of EV-based biomedical applications.
Key findings
Extracellular vesicles (EVs) are emerging as promising carriers for the delivery of therapeutic biologics.
Genetic engineering represents a robust strategy for loading proteins of interest into EVs.
Identification of EV-enriched proteins facilitates protein cargo loading efficiency.
Many EV-enriched proteins are sorted into EVs via an endosomal sorting complex required for transport (ESCRT)-dependent pathway.
Echo Biotech Role
Echo Biotech contributed EV isolation and purification; the study also used or cited Exosupur®.
Related platforms: Exoomics®, Research Reagents & Tools
Related services and capabilities: EV Isolation & Purification, Research Reagent / Product Supply
Related products or reagents: Exosupur® EV Isolation/Purification Kit
References
Original publication: Extracellular vesicle surface display of αPD-L1 and αCD3 antibodies via engineered late domain-based scaffold to activate T-cell anti-tumor immunity Journal of Extracellular Vesicles. 2024. DOI: 10.1002/jev2.12490. PMID/PMCID: 39051742; PMC11270581.